Peringkat dalam Saham
#35164
Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated... Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicelโa specialized cell therapyโhas successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.
Harga Saham
$0.0327
Terakhir disinkronkan: 2025-06-17
Kapitalisasi Pasar
$4.34M
Perubahan (1 tahun)
0.00%
Perdagangan Gamida Cell Ltd. (GMDA)
Harga GMDA dengan kapitalisasi pasar B
Kapitalisasi pasar dari Gamida Cell Ltd.(GMDA)
Kapitalisasi Pasar: $4.34M
Per August 2026, Gamida Cell Ltd. memiliki kapitalisasi pasar sebesar $4.34M. Ini menjadikan Gamida Cell Ltd. sebagai perusahaan 35164th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Gamida Cell Ltd. dari 2018 hingga 2026
GMDA dibandingkan dengan 5 teratas stocks paling populer
| Harga GMDA |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.452T
|
+125,692,588.97%
|
|
|
|
|
$4.490T
|
+103,517,214.83%
|
|
|
|
|
$4.162T
|
+95,964,100.96%
|
|
|
|
|
$3.676T
|
+84,757,892.92%
|
|
|
|
|
$2.833T
|
+65,315,634.53%
|